Randomized Trialhigh evidence
Safety, tolerability, and efficacy of RIPK1 inhibitor, SAR443820, in amyotrophic lateral sclerosis (HIMALAYA): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
The Lancet. Neurology·October 1, 2026·PMID 42716044
Why it mattersRIPK1 inhibition was a mechanistically promising approach for ALS, but this well-powered trial found no functional benefit and a concerning hepatic safety signal. These results definitively close this therapeutic avenue and reinforce the importance of rigorous phase 2 testing before advancing neuroprotective candidates.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled